ENDORSEMENT LICENSING AND CO-BRANDING AGREEMENT This ENDORSEMENT LICENSING AND CO-BRANDING AGREEMENT is entered into on July 26, 2013 (the "Effective Date”) by andbetween Marine MP, LLC (“Lender”), for services of Arnold Schwarzenegger (“Endorser”), and Fitness Publications, Inc. (“Fitness”) (collectively,Lender, Endorser, and Fitness are referred to as the “AS Parties”) and MusclePharm Corporation with its principal place of business in Denver,Colorado and its subsidiaries, (collectively, “MusclePharm” or the “Company”). RECITALS WHEREAS, the AS Parties have the rights necessary to license the use of the rights of publicity with respect to name, voice, approvedsignature, approved photographs, approved images, and approved likenesses of Arnold Schwarzenegger (the “Name and Appearance Rights”) andthe use of the Name and Appearance Rights as trademarks or service marks (the “Trademarks”); and WHEREAS, MusclePharm is engaged in the business of developing and marketing nutritional products for athletes and fitnessenthusiasts, and WHEREAS, MusclePharm from time to time uses consumer, celebrity, and expert endorsements or testimonials to promote MusclePharmProducts (as defined in Section 2(b) of this Agreement) in marketing and advertising materials, and WHEREAS, MusclePharm desires to develop, market, promote and sell in conjunction and in cooperation with the Endorser a uniqueArnold Schwarzenegger customized product line approved by the Endorser initially comprised of between four to eight (4 to 8) products, subject toSection 2(b) below), that will be marketed and advertised under the Endorser’s name and likeness, all subject to the Endorser’s approval, asdescribed in Section 12, (the “AS Product Line”); and WHEREAS, MusclePharm desires to engage Endorser, and Endorser desires to accept the engagement, as more fully described in thisAgreement, whereby Endorser will lend his name, reputation, and appearance to (i) endorse and promote MusclePharm and its Products and (ii) todevelop the AS Product Line and several related promotional giveaway items that will depict the Endorser’s name and likeness solely inconjunction with the MusclePharm logo or images of the AS Product Line on the permitted promotional products (the “Promotional Products”) setforth on Exhibit A attached hereto, as may be amended in writing by the parties hereto from time to time (collectively, the Promotional Products andthe AS Product Line are referred to as the “Licensed Products”). NOW, THEREFORE, in consideration of the mutual promises and agreements set forth below, the parties agree as follows: Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 1. Term: (a) This Agreement shall have an Initial Term of three (3) years. The Term shall commence on July 23, 2013 and shall expire on July 22,2016, unless otherwise terminated earlier pursuant to Section 9 of this Agreement. The period from July 23, 2013 to July 22, 2014 shall be referred toas the “First Contract Year”. The period from July 23, 2014 to July 22, 2015 shall be referred to as the “Second Contract Year”. The period from July23, 2015 to July 22, 2016 shall be referred to as the “Third Contract Year”. (b) In the event that MusclePharm shall achieve Net Sales (as defined below) of 20 million (the “First Renewal Threshold”) in theaggregate during the Third Contract Year, then this Agreement shall automatically be renewed for an additional term of three (3) years (the “FirstAdditional Term”) on the same terms and conditions for the Initial Term except that: (i) no additional Stock Compensation (as defined below) shallbe issued in connection with the renewal Term, (ii) the Cash Compensation for the First Additional Term shall be as set forth in Section 7 andExhibit “C” Section (2) attached hereto, (iii) Endorser shall only be obligated to make two (2) Appearances in each Contract Year during the FirstAdditional Term pursuant to Section 4(a)(ii) below and (iv) the marketing budget to promote the Licensed Products shall be 5.0 million during eachContract Year of the First Additional Term (subject to Section 12(b) of this Agreement). If this Agreement is renewed for the First Additional Term,then the First Additional Term shall commence on July 23, 2016, and the Agreement shall expire and terminate automatically without further noticeon July 22, 2019. (c) In the event that MusclePharm shall achieve Net Sales of 50 million (the “Second Renewal Threshold”) in the aggregate during thesixth Contract Year, then this Agreement shall automatically be renewed for an additional term of three (3) years (the “Second Additional Term”) onthe same terms and conditions for the initial Term except that: (i) no additional Stock Compensation (as defined below) shall be issued in connectionwith the renewal Term, (ii) the Cash Compensation for the renewal Term shall be as set forth in Section 7 and Exhibit “C” Section (3) attachedhereto, (iii) Endorser shall only be obligated to make two (2) Appearances in each Contract Year during the Second Additional Term pursuant toSection 4(a)(ii) below and (iv) the marketing budget to promote the Licensed Products shall be 5.0 in each Contract Year of the Second AdditionalTerm (subject to Section 12(b) of this Agreement). If this Agreement is renewed for the Second Additional Term, then the Second Additional Termshall commence on July 23, 2019 and the Agreement shall expire and terminate automatically without further notice on July 22, 2022. 2. Engagement: (a) MusclePharm hereby engages Endorser and Endorser promises and agrees to hold himself available to use, evaluate, advertise andpromote certain MusclePharm Products, as may be reasonably requested by MusclePharm in accordance with the terms and conditions set forthherein on a world-wide basis. Endorser also agrees to the use on a world-wide basis (as specified pursuant to Section 6 below and subject to theterms and conditions of this Agreement), during the Term, of his Name and Appearance Rights to advertise and promote the business ofMusclePharm, its Products, and the Licensed Products. Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 (b) Products. As used in this Agreement, “Products” shall mean dietary supplements manufactured within the fifty states of the UnitedStates of America; provided, however, MusclePharm shall not produce during the Term (and any renewal Term, if any) any diet pills and/or sexualenhancement products; provided, further, that fat burning products, Shred Matrix and Live Shredded products and products that increasetestosterone levels currently produced by MusclePharm as of the date hereof shall be part of the definition of Products for the purpose of thisAgreement. (c) New Products. During the Term (including any renewal Term, if any), in the event that MusclePharm shall determine to develop andintroduce a new Product into the market, MusclePharm shall provide the AS Parties with a sample of the name, design, marketing plan and an actualsample of such new Product (the “Sample”) and the AS Parties shall have a right of first refusal (exercisable by written notice to MusclePharmwithin 15 days after receipt of the Sample) to include such new Product in the AS Product Line, it being understood that there shall initially be noless than four (4) Products at the start of the Term and thereafter no more than 8 (eight) Products in the AS Product Line without the mutual writtenagreement of the parties hereto. (d) Distribution Channels Licensed Products. Subject to the terms and conditions herein (including the Exhibits), the license toMusclePharm with respect to distribution and promotion of the Licensed Products is on a worldwide basis through the Distribution Channels (asdefined below) subject to approval rights set forth in Section 13 herein. For the purposes of this Agreement, “Distribution Channels” means thedistribution of the Licensed Products through GNC retail and online chains worldwide during the First Contract Year and, thereafter, throughMusclePharm’s other worldwide distribution channels, as mutually determined by MusclePharm and the AS Parties. 3. Endorsement of Products: Endorser agrees that he will use and evaluate the Products and Licensed Products according to the recommended use and doseguidelines. Based on Endorser’s knowledge, personal use and experience with the Products and Licensed Products that he shall from time to timeduring the Term of this Agreement provide his honest evaluation, opinion, and findings about the Products and Licensed Products he is endorsingand promoting. The endorsements must be based on Endorser’s knowledge and/or personal use and experience with the Products and LicensedProducts at or about the times the endorsements are made. Endorser’s statements and endorsements, or paraphrases thereof, may be used byMusclePharm to advertise, promote and publicize its business, Products and Licensed Products as provided herein. Endorser’s endorsements ofthe Products and Licensed Products will be in accordance with the guidelines established by the Federal Trade Commission for endorsements inadvertising. If requested by MusclePharm, Endorser shall provide a signed affidavit in form satisfactory to MusclePharm confirming Endorser’scompliance with the FTC standards in connection with his endorsements and endorsement activities. Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 4. Appearances, Advertising and Promotional Activities: (a) Appearances and Video. (i) In order to ensure the success of the co-branded Licensed Products and maximize Net Sales of such Licensed Products to themutual benefit of the parties hereto, the Endorser agrees that he shall make four (4) personal appearances (“Appearances”) in the First ContractYear on dates, times and places mutually agreed upon by the parties hereto. Endorser acknowledges that such Appearances in the First ContractYear shall consist of: (i) one (1) appearance at an industry tradeshow to be mutually agreed by the parties, (ii) one (1) charity event with Arnold’sAll-Stars, (iii) one (1) appearance at the Arnold Classic, and (iv) one (1) corporate and public relations event(s) in 2013 to be mutually agreed by theparties. (ii) The Endorser and MusclePharm may also agree to produce on dates, times and places mutually agreed upon by the partieshereto a GetSwole training video (the “Training Video”) during a production session (the “Production Day”). In the event that Endorser shall agreeto produce the Training Video (such decision shall be made by the Endorser exercisable in his sole discretion) and Products (other than theLicensed Products) are featured and sold in connection with such Training Video then Endorser shall receive ten percent (10%) of Net Sales (asdefined below) from the sale of any Products other than the Licensed Products featured and sold directly in conjunction with the Training Video. (iii) In order to ensure the success of the co-branded Licensed Products and maximize Net Sales of such Licensed Products to themutual benefit of the parties hereto, the Endorser agrees that he shall make two (2) Appearances in each of the Second Contract Year and ThirdContract Year (and any subsequent Contract Years if applicable) on dates, times and places mutually agreed upon by the parties hereto (one suchappearance to include the Arnold Classic in each such Contract Year). (iv) Each Appearance may be up to two (2) hours in length not including travel time to and from the Appearance, as scheduled byMusclePharm, for the purpose or promoting MusclePharm, its Products and the Licensed Products. The Production Day shall be for the purpose ofMusclePharm shooting the Training Video. In the event that the Endorser agrees to participate in the Training Video, the Production Day for theTraining Video may be up to two (2) hours in duration. (v) In the event Endorser agrees to appear in the Training Video on television promoting the Licensed Products during the Termhereof, the Training Video shall be produced by a production company that is a SAG signatory and such production company shall pay on behalfof the Endorser all pension, health welfare benefit payments. For the purpose of computing such pension, health and welfare benefitcontributions and any other payments under any SAG or AFTRA contracts applicable to Endorsers appearance in such Training Video, 25% of thecompensation payable to Endorser under this Agreement shall be allocated as fair and reasonable consideration for Endorsers work andappearance in the Training Video during the Term or thereafter during the Use-Up Period defined below. Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 (b) Advertisements, Print Media, and Promotional Items. Endorser agrees that during the Term MusclePharm shall have the right to use,worldwide, Endorser’s Name and Appearance Rights (as specified in Section 6) to advertise MusclePharm and its Products and Licensed Productsin print media, and in all other forms of media (other than telephone marketing or texting campaigns) including, but not limited to, point of salematerial, premiums and novelties, direct marketing material, and radio, television, electronic, and computer media (including but not limited toMusclePharm’s Internet and social media websites). Print media will also include promotional items on which Endorser’s approved picture;approved likeness, or facsimile signature may appear. Endorser will have the right to approve, in writing via his representative’s office, alladvertising materials which utilize Endorser’s Name and Appearance Rights, but Endorser will not unreasonably withhold approval and willpromptly respond to all approval requests. (c) Use of Endorsements. During the Term, MusclePharm also shall have the right to use, worldwide, Endorser’s oral or writtenendorsements of Products and Licensed Products, or paraphrases thereof, to promote MusclePharm, its business, Products, and LicensedProducts. Endorser shall have the right to approve such oral or written endorsements and the use thereof, such approval not to be unreasonablywithheld or delayed. (d) Use-Up Period. During the Term, the right to use Endorsers Name and Appearance Rights granted to MusclePharm in this Sectionshall extend for six (6) months beyond the expiration of this Agreement (the "Use-up Period"). MusclePharm shall create no new advertising duringthe Use-up Period using Endorsers Name and Appearance, but shall have the right to use during the Use-up Period Endorsers Name andAppearance in advertisements and promotional materials created before the expiration date of this Agreement. (e) Promotional Products. During the Term, MusclePharm shall have the right to create and distribute the Promotional Products world-wide. MusclePharm shall be permitted to sell the Promotional Products at its cost to third parties and Endorser shall not be entitled to anyadditional compensation with respect to the Promotional Products. In the event that MusclePharm shall sell any Promotional Products above itscost then Endorser shall be entitled to receive 10% of Net Sales from the sale of such Promotional Products. (f) Online content. During the Term, Endorser will use good faith efforts to provide online content for MusclePharm’s websites and socialmedia websites as reasonably requested by MusclePharm. This will be in a form agreed to by the parties (e.g. training video or video interview witha MusclePharm representative). This will be scheduled so as to not interfere with Endorser’s movie and other obligations. Endorser will use goodfaith efforts to promote MusclePharm on his website (e.g. www.schwarzenegger.com). (g) GetSwole. Endorser, in conjunction with MusclePharm’s management and fitness experts will help in the design of the GetSwole Dietand Weight Training Program. (h) Autographed Items. Endorser shall also supply MusclePharm with at least fifty (50) signed items for each Contract Year, on theLicensed Products or on other items to be mutually agreed upon by the parties hereto, to be used by MusclePharm in connection with thepromotion of the Products and/or Licensed Products. Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 (i) Representations and Warranties. Endorser expressly represents and warrants that he is not subject to any restriction or limitation byway of employment or contractual obligation that may impair or limit his performance of the advertising and promotional activities described above,and that Endorser has the express approval of any third party to make the promises and commitments set forth herein, and will advise any futureemployer of his obligations hereunder. 5. Scheduling: (a) The Appearances, the Production Day, the Licensed Product launch and related media campaign, the interview of Endorser byMusclePharm, and all advertising and promotional activities requested by MusclePharm and approved by Endorser shall be scheduled by mutualagreement and subject to Endorser’s other business activities and commitments occurring during the Term of this Agreement. Endorser’scommitments pursuant to this Agreement shall be scheduled so as not to conflict with Endorser’s other commitments. Endorser agrees that he willin good faith make every reasonable effort, given his other commitments, to give priority to the fulfillment of his obligations pursuant to thisAgreement. The parties shall confer periodically for the purpose of coordinating and scheduling Endorser’s advertising and promotional activitiesand services. 6. Right of Publicity: (a) Name and Appearance Rights. As provided below, during the Term, the AS Parties grant to MusclePharm the right to use theTrademarks as defined in this Agreement and the Name and Appearance Rights, which shall include Endorser’s name, approved photograph,approved picture (including, without limitation, any copyrighted pictures and video images of the Endorser owned by the Endorser which Endorseragrees to make available for use hereunder), approved appearance, or approved likeness, including video and other recordings of Endorser’sappearance, along with the right to use Endorser’s voice, including audio or other recordings of Endorser’s voice, Endorser’s signature, personal orprofessional background and experience, reputation, approved quotations and approved endorsements, or approved paraphrases of Endorser’sapproved quotations and endorsements, including approved touch-ups, approved simulations or approved compositions of any of the abovewhether generated by computer or by any other means, for the period of time and for the purposes set forth in this Agreement. MusclePharmacknowledges that the use of some works may require that MusclePharm obtain a copyright license from third parties. (b) Promotional Uses. During the Term of this Agreement, the AS Parties grant to MusclePharm and consent to MusclePharm’s commercialuse of the Name and Appearance Rights to advertise, promote, endorse and publicize Products, Licensed Products, and MusclePharm’s business,worldwide in any media selected by MusclePharm (excluding telephone or texting campaigns), including but not limited to print, radio, television,electronic, wireless or internet, pursuant to the terms and conditions set forth herein. MusclePharm acknowledges that any use on productsrequires approval and that use of the Name and Appearance Rights on products is limited to the Licensed Products. Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 (c) Editorial Uses. Endorser also grants to MusclePharm and consents to MusclePharm‘s editorial use world-wide of Endorser’s Nameand Appearance in MusclePharm published materials approved by Endorser. For purposes of this Agreement, MusclePharm’s editorial use ofEndorser’s Name and Appearance shall mean a use that does not directly promote, advertise or endorse MusclePharm’s business, its Products orLicensed Products. Nothing in this Section 6(c) shall entitle MusclePharm to reduce Endorser’s compensation pursuant to Section 7 and Section 8of this Agreement (including, without limitation, with respect to any renewal Term, if any). (d) Discretion to Utilize. Except as otherwise provided in this Agreement, MusclePharm may in its sole discretion exercise some or all of therights granted by Endorser in this Agreement, but MusclePharm shall have no obligation to exercise or use the rights Endorser has granted. IfMusclePharm elects to not exercise or use all the rights granted by Endorser, MusclePharm’s election shall not be interpreted or construed as awaiver or release of such rights. MusclePharm shall have the rights to use Endorser’s Name and Appearance Rights and the Right to PublicizeEndorser’s Name and Appearance, as provided in this Agreement, unless Endorser and MusclePharm enter into a separate written agreement inwhich MusclePharm waives or releases some or all of the rights Endorser has granted in this Agreement. (e) Representations and Warranties. Endorser expressly represents and warrants that he is not subject to any restriction or limitation byway of employment or contractual obligation that may impair or limit the right of publicity granted herein by Endorser, and that Endorser has theexpress approval of his employer to make the promises and commitments set forth herein. 6A. News Releases and Public Announcements: Neither party may, without the other party’s prior written consent, make any news release or public announcement of the existence orvalue of this Agreement or its terms and conditions, or in any other manner advertise or publish its value, or its terms and conditions and neitherparty shall issue any press release or other public announcement which includes the name of the other party without such party’s prior writtenconsent, such consent not to be unreasonably withheld or delayed. The parties hereby agree that within four (4) business days after the executionand delivery of this Agreement and within four (4) business days after the launch of the Licensed Products, the parties hereto shall issue a jointpress release in form and substance mutually agreeable to the parties hereto. Notwithstanding the foregoing, a party may make any filing of thisAgreement or description of this Agreement in a current report on Form 8-K or similar requisite filing with the Securities and Exchange Commissionthat it believes in good faith and upon a reasonable basis is required by applicable law or any listing or trading agreement concerning its publiclytraded securities. 6B. Sample Products for Endorser’s Use: MusclePharm shall provide a reasonable supply of Products, Licensed Products, and Promotional Products for Endorser’s personal useand endorsement as contemplated by this Agreement. Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 7. Compensation: (a) Cash: (i)During the Term of this Agreement and during any sell-off period, MusclePharm shall pay Lender a royalty (the“Royalty”) of 10% on Net Sales (as defined below) of Licensed Products sold through its wholesale DistributionChannels or retail Distribution Channels, as the case may be and 10% on Net Sales of the Training Video and anyProducts sold in connection with any Training Video as contemplated pursuant to the last sentence of Section 4(a)(i)above. For purposes of this Agreement, "Net Sales" shall mean MusclePharms gross sales (the gross invoice amountbilled customers) of the Licensed Products, less discounts and allowances actually shown on the invoice (except cashdiscounts, transportation costs and commissions not deductible in the calculation of Royalty) and less any bona fidereturns (net of all returns actually made or allowed as supported by credit memoranda actually issued to the customersnot to exceed 5% in any reporting cycle), the aggregate of which discounts and allowances shall not exceed 5% in anyreporting cycle. No other costs incurred in the manufacturing, selling, advertising, and distribution of the LicensedProducts shall be deducted nor shall any deduction be allowed for any uncollectible accounts, allowances or bad debt. (ii)A Royalty obligation shall accrue upon the sale of the Licensed Products regardless of the time of collection byMusclePharm. For purposes of this Agreement, Licensed Products shall be considered “sold” upon the date when suchLicensed Products are billed, invoiced, shipped, or paid for, whichever event occurs first. (iii)If MusclePharm sells any Licensed Products to any party affiliated with MusclePharm, or in any way directly orindirectly related to or under the common control with MusclePharm, at a price less than the regular price charged toother parties, the Royalty payable to Lender shall be computed on the basis of the regular price charged to other parties. (iv)All payments due hereunder shall be made in United States currency drawn on a United States bank, unless otherwisespecified between the parties. (v)During the Term and during the sell-off period, MusclePharm shall make royalty payments in U.S. dollars for therespective quarters ending on the last day of September, December, March and June (each, a “Royalty Period”) withinthirty (30) days from the end of each quarterly period. Each such royalty payment shall include an itemized statementshowing the nature and source of such royalties, including (i) the number of units of Licensed Products sold (bycountry and customer); (ii) the total number of units returned for which credit was given and the total dollar amount ofsuch credits, and (iii) the total gross sales and the total royalties due with respect to such gross sales, and each itemizedstatement shall be certified by a duly authorized officer of MusclePharm. Such statements shall be in the form attachedhereto as Exhibit “B” and furnished to Lender whether or not any Licensed Products were sold during the RoyaltyPeriod. Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 (vi)MusclePharm will send all statements and payments, including all royalties, to the Lender to the address set forth inSection 20 below. MusclePharm will make all payments payable to the Lender. (vii)Receipt or acceptance by Lender (or its authorized representative) of a royalty statement or receipt or acceptance of anyaccompanying royalty payment shall not prevent Lender from at any time within three years after the Term of thisAgreement questioning the validity or accuracy of such royalty statement or payment. (viii)MusclePharm’s obligations for the payment of a Royalty and the Guaranteed Minimum Royalty (as defined below) shallsurvive expiration or termination of this Agreement and will continue for so long as MusclePharm continues tomanufacture, sell or otherwise market the Licensed Products. Notwithstanding the foregoing, Lender shall be entitled to receive a guaranteed minimum royalty for each Contract Year including theAdditional Term, if any (the “Guaranteed Minimum Royalty”), payable in accordance with Exhibit “C” attached hereto. 8. Stock: (a) Within three (3) days of the execution and delivery of this Agreement and prior to any news release or public disclosure of theexistence of this Agreement, its terms and conditions, or the relationship of the parties hereto, whether pursuant to a press release, a current reporton Form 8-K or other filing with the Securities and Exchange Commission or otherwise (the “Issuance Date”), MusclePharm shall issue Lender780,000 shares of MusclePharm’s restricted stock (the “Compensation Shares”), for services performed and to be performed pursuant to thisAgreement. All Compensation Shares will be fully vested upon issuance, and for a period of six (6) months following the date hereof, Lender maynot sell in excess of fifty percent (50%) of the Compensation Shares without the prior consent of MusclePharm; provided, that, the Lender shall beentitled, without the prior consent of MusclePharm, to transfer the Compensation Shares at any time to affiliates and family members so long assuch transfers are in compliance with state and federal securities laws and such transferees agree to be bound by foregoing transfer restrictions forthe six (6) month period following the date hereof with respect to the Compensation Shares. MusclePharm agrees that (i) with respect to theCompensation Shares, Lender shall be entitled to all rights and benefits under the registration rights agreement, dated as of March 28, 2013 (the“Registration Rights Agreement”), by and among MusclePharm and the investors party thereto as if it were an investor party thereto, mutatismutandis. MusclePharm shall promptly file (and in no event later than August 14, 2013) a registration statement on Form S-1 pursuant to theSecurities Act (as defined below) (the “Registration Statement”) with the SEC and will include therein the offering of all of the Compensation Sharesand no other securities of the Company. MusclePharm agrees that if the SEC shall issue comments on the Registration Statement, MusclePharmshall in good faith respond to such comments as soon as practicable. MusclePharm will cause the Registration Statement to be declared effective aspromptly as practicable. Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 (b) MusclePharm and Lender agree that, for purposes of determining the taxable income of Lender and the tax expense, deduction or othercorresponding charge of MusclePharm, in each case in connection with the issuance of the Compensation Shares in accordance with this Section 8,the fair market value of the Compensation Shares shall be the amount set forth in any third-party valuation report delivered by Lender toMusclePharm within forty-five (45) days following the Issuance Date. MusclePharm will promptly provide all information reasonably requested byLender and/or its valuation firm in connection with the preparation and delivery of such report. MusclePharm shall not take any position for taxpurposes inconsistent with such fair market value as so determined without the consent of Lender; provided, however, that nothing herein shallpreclude MusclePharm from utilizing a different method of calculating the fair market value of the Compensation Shares for financial accountingpurposes if MusclePharm’s Chief Financial Officer, audit committee and independent auditors shall determine in good faith that such alternativecalculation of the fair market value of the Compensation Shares is required under generally accepted accounting principles in the United States. (c) In connection with the issuance of the Compensation Shares, but without limitation of Section 8(a) or the other terms and conditions inthis Agreement, Lender hereby makes the following representations to MusclePharm regarding the Compensation Shares: (i) Lender understands that, as of the date hereof, none of the Compensation Shares have been registered under the SecuritiesAct of 1933, as amended (“Securities Act”), by reason of a specific exemption from the registration provisions of the Securities Act, the availabilityof which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of Lender’s representations asexpressed herein. Lender is acquiring all of the Compensation Shares for its own account, not as a nominee or agent, for investment and not with aview to, or for resale in connection with, any distribution or public offering thereof within the meaning of the Securities Act. (ii) Lender understands that all of the Compensation Shares will constitute “restricted securities” under the federal securitieslaws, inasmuch as it is being acquired from MusclePharm or such other company in one or more transactions not involving a public offering andthat under such laws the Compensation Shares may not be resold without registration under the Securities Act or an exemption therefrom. Thecertificates representing the Compensation Shares will be endorsed with a legend to such effect. Lender has been informed and understands that (i)there are substantial restrictions on the transferability of the Compensation Shares, and (ii) no federal or state agency has made any finding ordetermination as to the fairness for public investment, nor any recommendation nor endorsement, of the Compensation Shares. (iii) Lender, or Lender’s business and financial advisors, have substantial experience in evaluating and investing in privatetransactions of securities in companies similar to MusclePharm and such other company and Lender acknowledges that it can protect its owninterests. Lender, or such advisors, have such knowledge and experience in financial and business matters so that it is capable of evaluating themerits and risks of its acceptance of all of the Compensation Shares of MusclePharm as compensation or otherwise. Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 (iv) Lender is an “accredited investor” within the meaning of Rule 501 of Regulation D promulgated under the Securities Act. (v) Lender understands that all books, records, and documents of MusclePharm relating to it have been and remain available forinspection by him or his business and financial advisors upon reasonable notice. Lender confirms that all documents requested have been madeavailable, and that it or such advisors have been supplied with all of the information concerning MusclePharm that has been requested. Lenderconfirms that it or such advisors have obtained sufficient information, in its and their judgment to evaluate the merits and risks of receipt of theCompensation Shares as compensation or otherwise. Lender confirms that it has had the opportunity to obtain such independent legal and taxadvice and financial planning services as it has deemed appropriate prior to making a decision to enter this Agreement. In making each suchdecision, Lender has relied exclusively upon its experience and judgment, or that of such advisors, upon such independent investigations as it, orthey, deemed appropriate, and upon information provided by MusclePharm in writing or found in the books, records, or documents ofMusclePharm. (vi) Lender is aware that the economic ownership of the Compensation Shares is highly speculative and subject to substantialrisks. Lender is capable of bearing the high degree of economic risk and burdens of this venture, including, but not limited to, the possibility of acomplete loss, the lack of a sustained and orderly public market, and limited transferability of the Compensation Shares, which may make theliquidation thereof impossible for the indefinite future. (vii) The offer to issue the Compensation Shares as compensation to Lender was directly communicated to Lender or its businessor financial advisors by such a manner that it or such advisors were able to ask questions of and receive answers from MusclePharm or a personacting on its behalf concerning this Agreement. At no time was Lender presented with or solicited by or through any leaflet, public promotionalmeeting, television advertisement, or any other form of general advertising. (viii) None of the following information has ever been represented, guaranteed, or warranted to Lender, expressly or byimplication by any broker, MusclePharm, or agent or employee of the foregoing, or by any other person: (1) The approximate or exact length of time that Lender will be required to remain as a holder of any of the CompensationShares; (2) The amount of consideration, profit, or loss to be realized, if any, as a result of owning any of the CompensationShares; or (3) That the past performance or experience of MusclePharm, its officers, directors, associates, agents, affiliates, oremployees or any other person will in any way indicate or predict economic results in connection with the plan of operations of MusclePharm orthe return on any of the Compensation Shares. Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 (d) MusclePharm represents, warrants and covenants to Lender that: (i) It has the full right, power and authority to enter into this Agreement and to perform its obligations hereunder; (ii) it hasacquired all rights necessary to perform this Agreement and exploit the Licensed Products as contemplated herein; (iii) the Licensed Products, anyelement thereof, or any advertising, promotional or publicity materials supplied by Licensee or third parties hereunder will not contain any languageor material which is obscene, libelous, slanderous or defamatory; and (iv) the use of the Licensed Product and the Lender’s Name and Appearancerights as contemplated herein will not violate or infringe the copyright, trademark, or other rights of any third party. (ii) It has duly executed and delivered this Agreement and, assuming due authorization, execution and delivery by Lender, thisAgreement constitutes its legal, valid and binding agreement, enforceable against it in accordance with its terms. (iii) It is duly organized, validly existing and in good standing under the laws of the State of Nevada. It has all requisite power toown its properties and to carry on the business as it is now being conducted and is intended to be conducted and is duly licensed or qualified todo business in each jurisdiction in which the nature of its business or the ownership or leasing of its properties makes such license or qualificationnecessary. (iv) Neither the execution, delivery nor performance by it of this Agreement does or will (a) violate, conflict with or result in thebreach of any provision of its organizational documents, (b) conflict with or violate any law or governmental authorization applicable to it or any ofits assets or its business, or (c) conflict with, result in any breach of, constitute a default (or event which with the giving of notice or lapse of time,or both, would become a default) under, require any consent under, or give to others any rights of termination, amendment or acceleration of, orresult in the creation of any encumbrance on any of its assets pursuant to, any note, bond, mortgage or indenture, contract, agreement, lease,license, permit or franchise to which it is a party or by which any of its assets is bound or affected. (v) It has timely filed all reports, schedules, forms, statements and other documents required to be filed by it with the SECpursuant to the reporting requirements of the Exchange Act (all the foregoing filed prior to the date hereof and all exhibits included or incorporatedby reference therein and financial statements and schedules thereto and documents included or incorporated by reference therein being sometimeshereinafter collectively referred to as the “SEC Reports”). As of their respective filing dates, the SEC Reports complied in all material respects withthe requirements of the Exchange Act applicable to the SEC Reports (as amended or supplemented), and none of the SEC Reports, at the time theywere filed with the SEC, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein ornecessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 (vi) Set forth on Schedule 8(c) attached hereto is a true, complete, and accurate capitalization table of MusclePharm as of the datehereof on a fully diluted basis, taking into account all equity interests of MusclePharm issued or outstanding, or issuable upon conversion orexchange of any security, and any rights, options, or warrants or other agreements to acquire any such equity interests. 9. Termination: (a) This Agreement may be terminated by MusclePharm only: (i) In the event Endorser is convicted of a felony. (ii) In the event Endorser is in material breach or default of this Agreement, then MusclePharm may give written notice to Endorserof its intent to terminate this agreement and in such notice shall set forth in reasonable detail the facts, circumstances or events causingthe alleged breach or default (“Endorser Events of Default”). The Endorser shall have thirty (30) days’ notice in which to cure the EndorserEvents of Default to the reasonable and objective satisfaction of Musclepharm. If the Endorser fails, refuses or is unable for any reason tocure the Endorser Events of Default to the reasonable and objective satisfaction of MusclePharm, then MusclePharm may terminate thisAgreement by giving a written termination notice which shall be effective on third calendar day after the date of such termination notice. (iii) This Agreement may also be terminated by MusclePharm, upon fifteen days prior written notice, if death, or physical disability,physical injury, or other incapacity lasting more than eight (8) weeks, causes Endorser to be unable to perform a material amount of thepersonal or consulting services described in this Agreement. (b) This Agreement may be terminated by the AS Parties only: (i) In the event MusclePharm shall default under any indebtedness or financial obligations owed by MusclePharm in an amount inexcess of 1,000,000 including, without limitation, any failure to pay principal or interest thereon, and such event of default or conditionshall continue after any applicable grace period specified in such agreement or instrument, and the effect of such event or conditionresults in an actual acceleration of the maturity of such indebtedness or obligations; and/or (ii) If MusclePharm (A) dissolves, liquidates or otherwise terminates its business or operations; (B) shall generally not pay itsdebts or obligations as the same become due; (C) commences or becomes the subject of any case or proceeding under the bankruptcy,insolvency or equivalent laws of the United States or any other jurisdiction in the Territory which is not dismissed within 45 days; (D) hasappointed for it or for any substantial part of its property a court-appointed receiver, liquidator, assignee, trustee, custodian, sequestratoror other similar official which is not dismissed within 45 days; (E) makes an assignment for the benefit of its creditors; or (F) takescorporate action in furtherance of any of the foregoing; and/or Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 (iii) If the Company shall have (or with respect to the Company, the Chief Executive Officer or the Chief Financial Officer of theCompany shall have) (A) been charged with respect to a felony; (B) been sued by a governmental agency; (C) received a subpoena from agovernmental entity relating to an investigation of the Company; or (D) become the subject of an investigation by a governmental agencythat, in each case, if adversely determined, could have, as determined by Endorser in good faith (or, solely with respect to clause (D), asreasonably determined by the Endorser), a material adverse effect on the Company’s reputation or financial performance; and/or (iv) If the AS Parties reasonably determine (based either on (A) internal MusclePharm information; (B) reports or other credibleinformation produced by established medical or scientific experts; or (C) multiple adverse events reported to MusclePharm or in the media)that any of MusclePharms products are harmful to the human body or unsafe. (v) In the event Musclepharm is in material breach or default of this Agreement, the AS Parties may give written notice toMusclepharm of intent to terminate, and such notice shall set forth in reasonable detail the facts, circumstances or events causing thealleged breach or default (“MusclePharm Events of Default”). Musclepharm shall have thirty (30) days’ notice in which to cure theMusclePharm Events of Default to the reasonable and objective satisfaction of the terminating party. If Musclepharm fails, refuses or isunable for any reason to cure the MusclePharm Events of Default to the reasonable and objective satisfaction of the terminating party,then the the AS Parties may terminate this Agreement by giving a written termination notice which shall be effective on third calendar dayafter the date of the termination notice (c) Effect of Expiration/Termination: Upon expiration or termination of the Agreement for pursuant to Section 9 herein, Endorser shall haveno further obligation to render any services whatsoever. MusclePharm shall have no further right to use the rights granted to MusclePharmhereunder and all such rights (including without limitation the rights to use the Name and Appearance Rights and Trademarks) shall immediatelyand automatically be revoked and shall terminate and revert to the AS Parties immediately with no “use-up period”. Notwithstanding the foregoing,in the event the expiration of this Agreement or termination of this Agreement by Musclepharm pursuant to paragraph 9(a), MusclePharm shall beentitled to sell-off the remaining Licensed Products for six (6) months after such expiration of this Agreement pursuant to paragraph 4(d) herein andshall continue to pay Endorser the Royalty set forth in paragraph 7 herein. MusclePharm shall not be liable to pay any compensation for servicesperformed after the expiration or termination. In the event of a termination by MusclePharm pursuant to paragraph 9(a)(i)-(ii), Musclepharm shall notbe required to pay Endorser any further compensation except for Royalties earned up until such termination date, and provided, however, that ifMusclepharm terminates this Agreement because of death, disability, physical injury, or other incapacity of Endorser, if Endorser has performed allservices required by this Agreement for a particular Contract Year, then MusclePharm shall continue to be obligated to compensate Lender with thefull compensation amount of this Agreement for such Contract Year. Notwithstanding anything contained herein, irrespective of the expiratation ortermination of this Agreement, the AS Parties shall always be entitled to retain and shall never be obligated to return any monies paid and/or stockissued to Lender and/or Endorser pursuant to this Agreement. All formulas used in the Licensed Products shall remain the property ofMusclePharm, but all rights in any packaging, promotional materials, and websites of the Licensed Products (including, without limitation, pictures,the name, logos and trade dress) and all intellectual property of the AS Parties shall revert back or otherwise be vested in the AS Parties; provided,however, that the MusclePharm trade name, any MusclePharm trademarks, and MusclePharm logo used on the Licensed Products shall remain theproperty of MusclePharm. The AS Parties shall also have the right to purchase from MusclePharm the Arnold.com domain name for a purchaseprice equal to MusclePharm’s actual cost in acquiring such domain name (in the amount of Twenty Seven Thousand Five Hundred (27,500) plusinterest accruing at an annual rate of five percent (5%) from April 27, 2013 the date of acquisition of such domain name through the date of the saleof such domain name. Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 10. Expenses: In connection with any Appearance or Production Day that Endorser shall be required to specifically travel solely for MusclePharm tomake such Appearance or Production Day and shall not already be in such geographic location for another commitment, MusclePharm shall berequired to pay the expenses associated with Endorser’s travel, lodging, security and other expenses as set forth on Exhibit “D” attached hereto. 11. Audit Rights: (a) The AS Parties shall have the right, upon at least five (5) days written notice and no more than once each Contract Year of the Term toinspect MusclePharm’s books and records and all other documents and material in the possession of or under the control of MusclePharm withrespect to the Licensed Products at the place or places where such records are normally retained by MusclePharm. The AS Parties shall havereasonable access thereto for such purposes and shall be permitted to be able to make copies thereof and extracts therefrom. (b) MusclePharm shall keep complete and accurate books of account for the preceding three years from the date of termination andexpiration. In the event that any shortfalls, inconsistencies or mistakes are discovered, they shall immediately be rectified by MusclePharm at itssole cost and expense. (c) In the event a shortfall in the amount of five percent (5%) or more is discovered, MusclePharm shall reimburse the AS Parties for thecost of the audit including any reasonable attorney’s fees incurred in connection therewith. (d) MusclePharm agrees to preserve and keep accessible and available to the AS Parties all relevant books and records for a period of atleast three (3) years following the expiration or termination of the Agreement. 12. Sales and Marketing Plan And AS Product Line and Trademarks: (a) MusclePharm shall utilize its commercially reasonable efforts to advertise and promote the Licensed Products at its own expense and tosell the Licensed Products through the Distribution Channels worldwide as contemplated herein during the Term and to promote both the goodwillof the Endorser and the market reputation of the Licensed Products. MusclePharm will conduct its activities relating to the marketing of theLicensed Products in a professional manner. In that connection: Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 (b) Prior to the execution and delivery of this Agreement with respect to the First Contract Year and at least ninety (90) days prior to thebeginning of each Contract Year of the Term, MusclePharm will provide the AS Parties with a detailed marketing plan (the “Marketing Plan”). TheAS Parties shall be entitled to approve the Marketing Plan, such approval not to be unreasonably withheld or delayed. MusclePharm shall use itscommercially reasonable efforts to market and distribute the Licensed Products, and MusclePharm shall allocate between 3,000,000 and 5,000,000in the First Contract Year and 5,000,000 in each subsequent Contract Year (including any renewal terms if any) toward the marketing of theLicensed Products (the “Marketing Budget”); it being understood that the parties may mutually decide not to deploy the full Marketing Budget inany Contract Year if in the good faith determination by the parties that the deployment of the full Marketing Budget is unnecessary to achieve itsprojected revenue targets in connection with the sale of the Licensed Products. Notwithstanding the foregoing, MusclePharm shall be entitled tore-allocate marketing dollars in its good faith judgment exercisable in its sole discretion from the media forms set forth in the Marketing Plan topromote the Licensed Products in other media forms. (c) AS Product Line and Trademarks. The parties hereto agree and understand that the AS Product Line will be marketed and promoted asa distinct product line from MusclePharm’s overall product lines. Any trademarks and trade dress used as the brand of the AS Product Line shall beowned by the AS Parties (as among them, to be determined among them) and shall be included within the defined term Trademarks as used in thisAgreement. Any trademark used as a brand for an individual product in the AS Product Line, as opposed to a brand for the line of products,whether or not is based upon or derived from the Name and Appearance Rights or is independently developed also shall be owned by the ASParties (as among them, to be determined among them) and as shall be included within the defined term Trademarks as used in this Agreement.Notwithstanding the foregoing, the MusclePharm trade name, any MusclePharm trademarks, and MusclePharm logo used on the LicensedProducts shall remain the property of MusclePharm. 13. Quality Control: (a) MusclePharm acknowledges and agrees that, in order to maintain the goodwill and integrity of the Endorser, the Name and AppearanceRights, and the Trademarks (the “Endorser IP”), the Licensed Products shall be of a standard and of such style, appearance and quality as toprotect and enhance the goodwill associated with the Endorser IP, which standard the AS Parties may from time to time prescribe and which, in anyevent, shall be of substantially the same or better quality than the samples previously provided by MusclePharm to Endorser. To this end,MusclePharm will use the approval form attached hereto as Exhibit “E” to obtain required approvals under this Agreement (including, ingredientscontained in the Licensed Products). Prior to any use of any of the Endorser IP, MusclePharm shall submit to the AS Parties for the AS Parties priorwritten approval all artwork, photos, images, writings, advertising campaigns, slogans, claims made and other Name and Appearance Rightsassociated with the Endorser IP, samples of materials and design of the Licensed Products on which the Endorser IP are to appear and of alladvertising, press and promotional literature which MusclePharm intends to use in the marketing or merchandising of the Licensed Products usingthe submission form in Exhibit “E” attached hereto. The AS Parties shall respond to any such approval request within ten (10) business days. Tothe extent that the AS Parties shall fail to respond within such ten (10 day) period, the submissions shall be deemed disapproved. ShouldMusclePharm desire to submit the same request for approval, the AS Parties shall respond within five (5) days detailing the reason for disapproval.Should the AS Parties fail to respond in this last Five (5) business day period, submission shall be deemed approved. In addition, MusclePharmshall send, at its expense, at a minimum, two (2) representative samples of each Licensed Products, at each of the concept, pre-production andproduction stages, to the AS Parties at the address set forth in Section 20 below for prior approval. During the Term, MusclePharm will also sendtwo (2) representative samples of the Licensed Products to the AS Parties at the address set forth in Section 20 below upon request so that the ASParties can determine whether the quality of the Licensed Products bearing the Endorser IP is being maintained. Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 (b) MusclePharm shall at all reasonable times during the Term (but no more than once during each Contract Year of the Term), and uponreasonable notice, permit the AS Parties to send their authorized representatives to inspect the facilities of MusclePharm or its agents in order toconfirm that the production of the Licensed Products hereunder is in compliance with the quality standards set out herein and, at MusclePharm’sexpense, randomly test the formulas of the Licensed Products for quality control purposes, although the AS Parties will have no obligation to doso. (c) The Licensed Products shall be of the highest quality and manufactured, produced, sold, distributed and promoted in strict compliancewith all applicable laws and regulations, and be of substantially the same or better quality as the samples previously submitted by MusclePharm.MusclePharm shall be responsible for ensuring that the products are properly designed and manufactured for safe use and shall promptly and fairlyaddress and resolve all consumer complaints and warranty claims. MusclePharm hereby acknowledges that the AS Parties are not competent todetermine whether the products are safe for sale and/or distribution to the public at large. Accordingly, the AS Parties’ approval rights relate toaspects of quality and not to a determination of the safety of the products and any approvals given by the AS Parties of the products shall in noway detract from the MusclePharm’s obligations hereunder. (d) The License Products will be doctor-formulated and clinically tested at Stanford University or North Carolina University or anotheruniversity mutually acceptable to the parties hereto to prove the effectiveness of the Licensed Products. All Licensed Products will be tested byInformed Choice or another independent testing laboratory mutually acceptable to the parties hereto to be certified “Banned Substance Free” forathletes. (e) Manufacturers will comply with the requirements set forth in this Section 13(e): (i) MusclePharm and the manufacturers will not use child labor (not including child actors or models) in the manufacturing,packaging, marketing, advertising, or distribution of the Licensed Products. Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 (ii) MusclePharm and the manufacturers will only employ persons whose presence is voluntary. MusclePharm and themanufacturers will not use any forced or involuntary labor. (iii) MusclePharm and the manufacturers will treat each employee with dignity and respect, and will not use corporal punishment,threats of violence, abuse, or other forms of physical, sexual, psychological, or verbal harassment. (iv) MusclePharm and the manufacturers will not unlawfully discriminate in any hiring or employment practices. (v) MusclePharm and the manufacturers will, at a minimum, materially comply with all applicable wage and hour laws, rules,regulations, and industry standards. MusclePharm and the manufacturers agree that, where local industry standards are higherthan applicable legal requirements, MusclePharm and manufacturer will meet the higher local standards. (vi) MusclePharm and the manufacturers will materially comply with all applicable workplace laws, rules, regulations, and industrystandards, ensuring, at a minimum, reasonable access to potable water and sanitary facilities, fire safety, and adequate lightingand ventilation. (vii) MusclePharm and the manufacturers will respect the rights of employees to associate, organize, and bargain collectively in alawful and peaceful manner, without penalty or interference. (viii) MusclePharm and the manufacturers will materially comply with all applicable environmental laws, rules, regulations, andindustry standards. (ix) If MusclePharm becomes aware that any manufacturer has used or is using Endorser IP for any unauthorized purpose,MusclePharm, will immediately notify the AS Parties and, if so instructed by the AS Parties, will cause such manufacturer tocease such use immediately. (f) Unless the AS Parties expressly agree in advance and in writing otherwise, all Licensed Products shall be manufactured within the fiftystates of the United States of America and in no other locations. 13A. Ownership and Registration of Trademarks and Name and Appearance Rights: (a) During the Term and after expiration or termination of this Agreement, MusclePharm shall not contest or otherwise challenge or attackthe AS Parties’ rights in the Trademarks or Name and Appearance Rights or the validity of the license being granted herein. (b) During the Term and after expiration or termination of this Agreement, MusclePharm shall not use any trademark which so substantiallyresembles any of the Trademarks or Name and Appearance Rights as to be likely to deceive or cause confusion or mistake or which might amountto passing-off; provided however, nothing herein shall preclude MusclePharm from using any of the intellectual property to be retained byMusclePharm contemplated pursuant to Section 9(f) of this Agreement after the termination of this Agreement. Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 (c) MusclePharm recognizes the value of the good will associated with the Trademarks and Name and Appearance Rights andacknowledges that the Trademarks and Name and Appearance Rights, and all rights therein and the good will pertaining thereto, belong exclusivelyto the AS Parties. (d) MusclePharm agrees that its use of the Trademarks and Name and Appearance Rights shall inure to the benefit of the AS Parties andthat MusclePharm shall not, at any time, acquire any rights in the Trademarks and/or Name and Appearance Rights by virtue of any use it may makeof the Trademarks and/or Name and Appearance Rights. (e) MusclePharm agrees that any copyrights in works created based upon the Trademarks and/or Name and Appearance Rights shallbecome the rights of the AS Parties (as among them to be determined among them). MusclePharm irrevocably and unconditionally transfers andassigns to the AS Parties in perpetuity and throughout the universe any and all of MusclePharm’s right, title, and interest, if any (including, withoutlimitation, the rights generally known as ‘moral rights’) in and to all works, including any packaging, advertising and promotional materials, andother materials based upon the Trademarks and/or Name and Appearance Rights, all of which shall, upon their creation, become and remain theproperty of the AS Parties. All such works based upon the Trademarks and/or Name and Appearance Rights shall be prepared by an employee-for-hire of MusclePharm (under MusclePharms’s sole supervision, responsibility, and monetary obligation) or as a work-for-hire by a third party whoassigns to the AS Parties in writing and in perpetuity throughout the universe all right, title, and interest in the same provided however, nothingherein shall preclude MusclePharm from using any of the intellectual property to be retained by MusclePharm contemplated pursuant to Section9(f) of this Agreement after the termination of this Agreement. (f) Injunctive Relief. MusclePharm acknowledges that the unauthorized use of the Name and Appearance Rights and Trademarks will resultin immediate and irreparable damages to the AS Parties and that the AS Parties would have no adequate remedy at law for such authorized use.MusclePharm further agrees that in the event of any unauthorized use of the Name and Appearance Rights and/or the Trademarks, the AS Parties,in addition to all other remedies available to them hereunder, shall be entitled to injunctive relief against any such unauthorized use as well as suchother relief as any court with jurisdiction may deem just and proper. (g) Registration. If the AS Parties decide in their sole discretion after consulting with MusclePharm to register the Trademarks and/or NameAnd Appearance Rights as a trademark for the Licensed Products and/or any Promotional Products or to register the copyrights in any worksbased upon the Trademarks and/or the Name And Appearance Rights, MusclePharm will cooperate to provide information, samples, anddocuments as reasonably requested by the AS Parties to enable the AS Parties to comply with the application, registration, license recordal, andother requirements of any applicable jurisdictions. If the AS Parties decide to register Trademarks and/or Name And Appearance Rights as atrademark for the Licensed Products, MusclePharm will reimburse the AS Parties for any reasonable expenses incurred in registering in the UnitedStates and Canada and such other countries as the parties shall mutually agree upon. Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 14. Independent Contractor: It is expressly agreed that Endorser is acting as an independent contractor in performing his services hereunder. MusclePharm shall carryno workers compensation insurance or any health, accident or disability insurance to cover Endorser. MusclePharm shall not pay anycontributions to Social Security, unemployment insurance, federal or state withholding taxes, nor provide any other contributions or benefits thatmight be expected in an employer-employee relationship. Endorser shall be solely responsible and liable for reporting and paying all federal andstate income or other taxes applicable to the Endorser’s compensation under this Agreement and MusclePharm will provide Lender with an IRSForm 1099 at the end of each calendar year in which compensation is paid to Lender. It is further understood and expressly agreed by Endorser thathe has no right or authority to incur expenses, obligations or liabilities in the name of or binding on MusclePharm, and he shall not represent tothird parties that he has any relationship (e.g., employer-employee or principal-agent) with MusclePharm other than the independent contractorarrangement set forth in this Agreement. 15. Indemnification. (a) By the AS Parties. The AS Parties will at all times indemnify and hold MusclePharm and its agents and licensees harmless from andagainst any and all claims, damages, liabilities, costs and expenses (including reasonable outside attorneys’ fees), arising out of any breach by theAS Parties of any warranty or agreement made by the AS Parties hereunder. In no event shall the AS Parties’ indemnification obligations toMusclePharm hereunder exceed the after-tax value of the Cash Consideration received by Lender under this Agreement. (b) By MusclePharm. MusclePharm agrees to protect, indemnify, save, defend, and hold harmless the AS Parties, their related companies,affiliates, and partners, and each of their assigns, agents, representatives, officers, directors, shareholders, and employees from and against anyand all expenses, damages, liabilities, claims, suits, actions, judgments, costs and expenses whatsoever (including reasonable attorney’s fees; boththose incurred in connection with the defense or prosecution of the indemnifiable claim and those incurred in connection with the enforcement ofthis provision), caused by, arising out of, or in any way connected with (i) any injury, death, or other harm or claim connected with, or claimeddefect in, Products or Licensed Products provided, manufactured, produced, marketed, promoted, sold, and/or distributed by MusclePharm(including any party affiliated with MusclePharm); (ii) any material inaccuracy or misrepresentation by MusclePharm in this Agreement; (iii) anyadvertisement and/or promotion of MusclePharm, its Products, or Licensed Products, including but not limited to any use of the materials producedpursuant to this Agreement, as well as MusclePharm’s advertising/promotion campaign described above in this Agreement and/or (iv) any breachof this Agreement and/or in connection with this Agreement. No settlement will be entered into by the AS Parties without MusclePharm’s priorwritten approval. Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 16. Exclusivity; Non-Competition: (a) During the term of this Agreement, or any extensions of this Agreement, Endorser and the Lender hereby agree and warrant that it willnot enter into any other endorsement agreement for the use of Endorser’s name, image and/or likeness for advertising, marketing and/orendorsement of any other dietary supplements during the Term of this Agreement. Notwithstanding the foregoing, the following will not be abreach of this Agreement: (i) Endorser’s performance of services or appearing in the news or informational portion of any radio, TV or film orentertainment program regardless of products or services therein or sponsorship thereof; (ii) Endorser’s participation in movies or TV programs aswell as merchandising, commercial tie-ins and/or product placements utilizing Endorser, or (iii) Endorser’s performance of services, appearance oruse of his name, likeness in connection with charitable events, sports events, organizations, regardless of usage of products or services and/orsponsorship thereof. (b) Endorser shall not use or provide endorsements or testimonials for products that compete with MusclePharm Products or the LicensedProducts. Any failure of Endorser to disclose such conflicting interests, or any breach of this Section, shall be deemed a material breach of theAgreement. Endorser’s duty not to compete with the business of MusclePharm shall continue for a period of one year following the expiration ortermination of this Agreement. Endorser’s non-competition obligation shall not be required in the event of a material breach of this Agreement byMusclePharm. (c) Notwithstanding the foregoing or anything else contained herein, this Agreement shall not prevent or shall in any manner restrictEndorser from advertising, marketing and or endorsing products (or other companies which manufacture such products) which incidentally containdietary supplements (including without limitation protein, vitamins, minerals, amino acids, herbs, legal performance enhancing substances)provided the primary purpose of such product or company is not to sell or market a dietary supplement. 17. [RESERVED.] 18. Assignment: The license granted by this Agreement is personal to MusclePharm. Except as set forth below, MusclePharm shall not assign or otherwisetransfer, license, sublicense, or delegate any rights or obligations under this Agreement without the express prior written consent of the AS Parties.Neither party shall voluntarily or by operation of law assign or otherwise transfer the rights and/or obligations incurred pursuant to the terms ofthis Agreement without the prior written consent of the other party. Any attempted assignment or transfer by a party of their rights and/orobligations without such consent shall be void. Nothwithstanding the foregoing, this Agreement may be assigned without the AS Parties’ consentby MusclePharm in connection with a change of control transaction; provided that the acquirer of MusclePharm shall have financial resourcessubstantially similar or greater than MusclePharm and shall specifically assume the obligations of MusclePharm under this Agreement in writingprior to the consummation of the change of control transaction. In addition, notwithstanding the foregoing, the Endorser and the Lender shall beentitled to sell, transfer and assign the Cash Compensation and the Compensation Shares (subject to compliance with the restrictions set forth inSection 8(a) above and federal and state securities laws) to third parties; provided, however, that Endorser shall remain solely liable to fulfill all ofhis obligations under this Agreement. Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 19. Modification of Agreement: The parties may modify this Agreement hereto only by a written supplemental agreement executed by both parties. 20. Notice: Any notice required or permitted to be given hereunder shall be sufficient if given in writing, and sent by registered or certified mail,postage prepaid, or by courier such as FedEx, addressed as follows: If to MusclePharm: MusclePharmAttn: Brad Pyatt; CEO4721 Ironton StreetDenver, CO 80237 With a copy to: Sichenzia Ross Friedman Ference LLP61 Broadway, 32nd FloorNew York, NY 10006Attn:Harvey J. Kesner, Esq.Edward H. Schauder, Esq If to the AS Parties: Arnold Schwarzeneggerc/o Main Street Advisors, Inc.3110 Main Street, Suite 310Santa Monica, CA 90405 Marine MP, LLC3110 Main Street, Suite 300Santa Monica, CA 90405ATTN: Arnold Schwarzenegger Fitness Publications, Inc.3110 Main Street, Suite 300Santa Monica, CA 90405ATTN: Arnold Schwarzenegger Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 With a copies to: Main Street Advisors3110 Main Street, Suite 310Santa Monica, CA 90405Attn: Paul Wachter Alex Cohen and Bloom Hergott Diemer Rosenthal LaViolette FeldmanSchenkman Goodman, LLP150 South Rodeo Drive, 3rd FloorBeverly Hills, CA 90212Attn: Patrick M. Knapp, Esq. and Loeb Loeb LLP10100 Santa Monica Blvd., Suite 2200Los Angeles, Ca 90067Attn: David W. Grace or to such other address as the parties hereto may specify, in writing, from time to time. Written notice given as provided in this Section shall bedeemed received by the other party two business days after the date the mail is stamped registered or certified and deposited in the mail, ordeposited with courier. 21. Governing Law: This Agreement has been executed and delivered in Los Angeles County in the State of California, and its interpretation, validity andperformance shall be construed and enforced in accordance with the laws of the State of California. The exclusive venue for any proceeding tointerpret, construe or enforce this Agreement in accordance with Section 22 below shall be Los Angeles County, California. 22. Dispute Resolution and Attorneys’ Fees: (a) Any dispute, claim or controversy arising out of or relating to this Agreement or the breach, termination, enforcement, interpretation orvalidity thereof, including the determination of the scope or applicability of this agreement to arbitrate, shall be determined by arbitration in LosAngeles County before an arbitrator who is a retired U.S. District Court judge. The arbitration shall be administered by JAMS pursuant to itsComprehensive Arbitration Rules and Procedures. Judgment on the Award may be entered in any court having jurisdiction. The parties adopt andagree to implement the JAMS Optional Arbitration Appeal Procedure (as it exists on the effective date of this Agreement) with respect to any finalaward in an arbitration arising out of or related to this Agreement. Nothing in this agreement clause shall preclude parties from seeking provisionalor injunctive relief remedies in aid of arbitration from a court of appropriate jurisdiction. Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 (b) In any arbitration arising out of or related to this Agreement, the arbitrator(s) shall award to the prevailing party, if any, the costs andattorneys’ fees reasonably incurred by the prevailing party in connection with the arbitration. If the arbitrator(s) determine a party to be theprevailing party under circumstances where the prevailing party won on some but not all of the claims and counterclaims, the arbitrator(s) mayaward the prevailing party an appropriate percentage of the costs and attorneys’ fees reasonably incurred by the prevailing party in connectionwith the arbitration. 23. Binding Effect: This Agreement when signed by the parties shall be binding upon the parties, and their respective heirs, successors or legalrepresentatives. 24. Representations, Warranties and Covenants: (a) The AS Parties represent and warrant that (i) they hold all such rights, title, and interest in his Name and Appearance Rights as arerequired to permit them to enter into this Agreement; (ii) they have the full right, power and authority to enter into this Agreement; (iii) they havenot authorized any third party to create products similar to the AS Product Line, and (iv) they do not own any equity interest in any companies thatproduce nutrition and/or supplement products. MusclePharm expressly acknowledges that the AS Parties have not ascertained the worldwideavailability of the Name and Appearance Rights and related Trademarks for use as trademarks on the Licensed Products or whether such use wouldinfringe the rights of any other entities. EXCEPT AS SPECIFICALLY SET FORTH HEREIN, THE AS PARTIES EXPRESSLY DISCLAIM ALLREPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, IN CONNECTION WITH THE TRADEMARKS AND NAME ANDAPPEARANCE RIGHTS, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF TITLE, NON-INFRINGEMENT OFINTELLECTUAL PROPERTY RIGHTS, MERCHANTABILITY, AND FITNESS FOR A PARTICULAR PURPOSE. THE AS PARTIES SHALL NOT BELIABLE TO MUSCLEPHARM OR ANY THIRD PARTY FOR ANY DAMAGES ARISING FROM OR RELATING TO MUSCLEPHARM’S USE OFTHE TRADEMARKS AND NAME AND APPEARANCE RIGHTS. IN NO EVENT SHALL THE AS PARTIES BE LIABLE FOR SPECIAL,CONSEQUENTIAL, OR PUNITIVE DAMAGES. (b) MusclePharm represents, warrants and covenants that (i) it has the full right, power and authority to enter into this Agreement; (ii) ithas acquired all rights necessary to perform this Agreement and exploit the Licensed Products as contemplated herein; (iii) the Licensed Products,any element thereof, or any advertising, promotional or publicity materials supplied by Licensee or third parties hereunder will not contain anylanguage or material which is obscene, libelous, slanderous or defamatory; (iv) the use of the Licensed Product and the Name and AppearanceRights as contemplated herein will not violate or infringe the copyright, trademark, or other rights of any third party; (v) the Products and LicensedProducts will comply in all material respects with all applicable laws and regulations and will be safe for human consumption. Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 25. Payments: All cash payments shall be made via wire transfer to the Lender to an account provided by Lender or his representative. 26. Confidentiality: The parties acknowledge that during the course of this Agreement the parties will provide to each other certain proprietary andconfidential information that is held and maintained confidentially by each party. Each party shall be entitled to share such confidential informationreceived by such party only with such party’s representatives, legal and accounting advisors who shall agree to be bound by the confidentialityobligations set forth in this Section 26. During the term of this Agreement and for three (3) years thereafter, each party shall hold in strictconfidence all such information. This obligation shall not apply to any information which: (a) becomes known to the general public through no faultof either party; (b) is required to be disclosed in the enforcement of rights hereunder, or (c) is required to be disclosed by any state or federal statue,regulation or court order. 27. Insurance: MusclePharm shall, throughout the Term of the Agreement and for a period of not less than four years thereafter, obtain and maintain at itsown cost and expense from a qualified insurance company licensed to do business in California and New York, a commercial general liabilityinsurance policy including coverage for contractual liability (applying to the terms and conditions of this agreement), product liability, personalinjury liability, and advertisers liability, in a form approved by the AS Parties, in the amount of at least Five Million Dollars (US5,000,000) peroccurrence naming the AS Parties (for the avoidance of doubt, specifically including each of Lender, Endorser, and Fitness) as additional namedinsureds. Without limiting the generality of the foregoing, such policy shall provide protection against any and all claims, demands, and causes ofaction arising out of any defects or failure to perform, alleged or otherwise, of the Products and Licensed Products or any material used inconnection therewith or any use thereof. The policy shall provide for ten (10) days notice to the AS Parties from the insurer by Registered orCertified Mail, return receipt requested, in the event of any modification, cancellation, or termination thereof. MusclePharm agrees to furnish the ASParties a certificate of insurance evidencing same within thirty (30) days after execution of this Agreement and, in no event, shall MusclePharmmanufacture, distribute, advertise, or sell the Licensed Products prior to receipt by the AS Parties of such evidence of insurance. MusclePharmshall be responsible to provide for any appearances pursuant to this Agreement by Endorser appropriate certificates of insurance with coveragelimits of at least Five Million Dollars (US5,000,000) per occurrence endorsed to name the AS Parties as additional named insureds with respect toclaims arising out of appearances by Endorser. MusclePharm shall be responsible to pay the deductible under any such insurance policies withrespect to any claims made under such policies. Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 28. Entire Agreement: This Agreement contains the entire contract of the parties with respect to the subject matter hereof and supersedes all agreements andunderstandings between the parties concerning the subject matter hereof. The language in all parts of this Agreement shall in every case beconstrued simply according to its fair meaning. 29. Infringement: (a) The AS Parties shall have the exclusive right, but not the obligation, to prosecute, defend, and/or settle at their own cost and expenseand in their sole discretion, all actions, proceedings and claims involving an infringement of the Name and Appearance Rights or Trademarks andto take any other action that they deem proper or necessary in their sole discretion for the protection and preservation of such rights. In their soleoption, the AS Parties may take any action described above in one or more of their own names and MusclePharm will cooperate fully therewith.MusclePharm shall have the exclusive right, but not the obligation, to prosecute, defend and/or settle at its own cost and expense and in its solediscretion, all actions, proceedings and claims involving an infringement of the MusclePharm trade name, trademarks, and logo even if the matterinvolves the Licensed Products and to take any other action that its deem proper or necessary in its sole discretion for the protection andpreservation of such rights. In its sole option, MusclePharm may take any action described above in its own name and the AS Parties willcooperate fully therewith if the matter involves the Licensed Products. All expenses of any action taken by a party hereto as contemplated aboveshall be borne by such party, and all relief granted in connection therewith shall be solely for the account of such party. A party hereto will notclaim or reserve any rights against the other party as the result of any such action contemplated above. (b) Each party shall notify the other party promptly of any adverse, pending or threatened action in respect of an infringement of the Nameand Appearance Rights or Trademarks or any infringement of the Licensed Products, as the case may be, and of any use by third parties thatwould or might tend to be adverse to the rights of the parties hereto, as applicable. THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK. Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 This Agreement when signed and dated by all parties shall be deemed to be made, accepted and delivered in the City and County of LosAngeles, California, regardless of where the Agreement is executed by the parties. MusclePharm Corporation By:/s/Brad Pyatt Name: Brad Pyatt Title:CEO Dated: July 26, 2013 Marine MP, LLC By:/s/ Paul Wachter Name: Paul Wachter Title: Manager Dated: July 26, 2013 By:/s/Arnold Schwarzenegger Arnold Schwarzenegger Dated: July 26, 2013 Fitness Publications, Inc. By:/s/Arnold Schwarzenegger Name: Title: Dated: July 26, 2013 Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 EXHIBIT A PROMOTIONAL PRODUCTS Promotional Products shall include the following products:T-Shirts;Golf Shirts;Hats;Visors;Wristbands and Headbands; andShakers. Each and every of the foregoing Promotional Products must be specifically approved in advance and in writing by the AS Parties and shall alwaysprominently include the MusclePharm logo or images of the Licensed Products. Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 Exhibit “B”Royalty Statement Company Name:MusclePharm Corporation Licensee Address:4721 Ironton Street, Unit A, Denver, Colorado 80239 For Quarter Ending:____________________ CustomerName Item/SKUNumber orDescription InvoicePrice No.UnitsSold SalesInvoice LessReturns NetSales RoyaltyPercentage RoyaltyAmount Total Royalty Earned This Quarter: Total Earned Royalty To Date (This Contract Year): TOTAL Less Paid and Un-Recouped Minimum Guarantee: ([ ]) Balance Due From the Company and Payable This Quarter: I hereby certify that the above is accurate and complete. Signature Date Title Printed Name Submit to: Name: Email: Tel: Date Received: Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 Exhibit “C” Section (1) Guaranteed Minimum Royalty during the initial Term: Contract Year Minimum Royalty Timing of PaymentOne 1,500,000 500,000 payment due on the following dates: July 23, 2013; October 1,2013; February 1, 2014Two 2,000,000 666,666.66 payment due on the following dates: July 23, 2014; October1, 2014; February 1, 2015Three 2,500,000 833,333.33 payment due on the following dates: July 23, 2015; October1, 2015; February 1, 2016 Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 Section (2) Guaranteed Minimum Royalty during the First Additional Term: In the event that the Renewal Threshold is achieved in the Third Contract Year, during the First Additional Term the Minimum Royalty and Timingof Payment shall be as follows: Contract Year Minimum Royalty Timing of PaymentFour 2,500,000 833,333.33 payment due on the following dates: July 23, 2016; October1, 2016; February 1, 2017Five 2,500,000 833,333.33 payment due on the following dates: July 23, 2017; October1, 2017; February 1, 2018Six 2,500,000 833,333.33 payment due on the following dates: July 23, 2018; October1, 2018; February 1, 2019 Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 Section (3) Guaranteed Minimum Royalty during the Second Additional Term: In the event that the Second Renewal Threshold is achieved in the Sixth Contract Year, during the Second Additional Term the Minimum Royaltyand Timing of Payment shall be as follows: Contract Year Minimum Royalty Timing of PaymentSeven 5,000,000 1,666,666.66 payment due on the following dates: July 23, 2019; October1, 2019; February 1, 2020Eight 5,000,000 1,666,666.66 payment due on the following dates: July 23, 2020; October1, 2020; February 1, 2021Nine 5,000,000 1,666,666.66 payment due on the following dates: July 23, 2021; October1, 2021; February 1, 2022 Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 Exhibit “D” Endorser Expenses MusclePharm shall be responsible for the following expenses:Exclusive private jet transportation (Netjets, or as otherwise indicated by Endorser) to be arranged through M. Paul Wachter or AlexCohen;A first class suite at a hotel of Endorser’s choice;A security detail; andA reasonable per diem expense allowance while Endorser is on location. Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 Exhibit “E”Approval Request Response Tracking Number: _____________________ CONCEPT: ________________________________ Date: __________________ Approved. Supply pre-production sample as soon as available for approval. Not approved, pending changes indicated. Re-submit concept sample for approval. Not approved. PRE-PRODUCTION SAMPLE: _____________________ Date: _____________ Approved. Supply production sample as soon as available for approval. Not approved, pending changes indicated. Re-submit pre-production sample for approval. Not approved. PRODUCTION SAMPLE: _______________________ Date: ______________ Approved. Supply production sample for Arnold Schwarzenegger’s records. Approved with changes for next production run please re-submit. Not approved, pending changes indicated. Re-submit production sample for approval. Not approved. Cease all manufacture, sale, display, marketing, and distribution. COMMENTS: Signature: Title: Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017